• Monday, Sep 27, 2021
  • Last Update : 01:35 pm

Gilead analysis shows remdesivir reduced Covid-19 death risk, more studies needed

  • Published at 11:42 am July 11th, 2020
Gilead
File photo: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (Covid-19), during the outbreak of the coronavirus disease (Covid-19), in Oceanside, California, US, April 29, 2020 Reuters

The US government trial in April showed that patients given remdesivir recovered 31% faster than those given a placebo

Gilead Sciences Inc said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill Covid-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.

Remdesivir has been at the forefront of the global battle against Covid-19 after the intravenously administered medicine helped shorten hospital recovery times, according to data in April from a separate US government trial.

That study showed a trend toward better survival for remdesivir but the difference was not statistically significant.

In the latest analysis, Gilead said it analyzed data from 312 patients treated in its late-stage study and a separate real-world retrospective cohort of 818 patients with similar characteristics and disease severity.

Gilead's late-stage study evaluated the safety and efficacy of five-day and 10-day dosing durations of remdesivir in hospitalized patients. The study did not have a placebo comparison.

Dr Susan Olender from Columbia University Irving Medical Center said in the Gilead statement that the analysis draws from a real-world setting and serves as an important adjunct to clinical trial data even as it is not as vigorous as a randomized controlled trial.

However, Dr Walid Gellad, a professor at University of Pittsburgh's medical school, called it "a joke" to compare clinical trial data with observational data and conclude anything definitive about mortality.

"The mortality in the remdesivir trials has generally been lower for both control and intervention groups than other trials and other real world cohorts I've seen," Gellad said in an email.

"The real world patients are taken care of at different hospitals than those in the trial and potentially different adjunct treatments. They're different."

Findings from the analysis showed that 74.4% of remdesivir-treated patients recovered by Day 14 versus 59.0% of patients receiving standard of care, the company said.

The mortality rate for patients treated with remdesivir in the analysis was 7.6% at Day 14, compared with 12.5% among patients not on remdesivir.

The US government trial in April showed that patients given remdesivir recovered 31% faster than those given a placebo.

Gilead's shares rose 2% to $76.27 in afternoon trading.

53
Facebook 51
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail